Garnett, MJ, Edelman, EJ, Heidorn, SJ, Greenman, CD, Dastur, A, Lau, KW, Greninger, P, Thompson, IR, Luo, X, Soares, J, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570–575.
Woodcock, J, Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008, 59:1–12.
Gibaldi, M, Levy, G. Pharmacokinetics in clinical practice. 2. Applications. JAMA 1976, 235:1987–1992.
Dettli, L. Individualization of drug dosage in patients with renal disease. Med Clin North Am 1974, 58:977–985.
Holford, NH, Sheiner, LB. Understanding the dose‐effect relationship: clinical application of pharmacokinetic‐pharmacodynamic models. Clin Pharmacokinet 1981, 6:429–453.
Lim, AK, Mathanasenarajah, G, Larmour, I. An assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance. Intern Med J 2015, 45:319–329.
Marangolo, M, Bengala, C, Conte, PF, Danova, M, Pronzato, P, Rosti, G, Sagrada, P. Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep 2006, 16:233–248.
Calvert, AH, Newell, DR, Gumbrell, LA, O`Reilly, S, Burnell, M, Boxall, FE, Siddik, ZH, Judson, IR, Gore, ME, Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748–1756.
Nagao, S, Fujiwara, K, Imafuku, N, Kagawa, R, Kozuka, Y, Oda, T, Maehata, K, Ishikawa, H, Koike, H, Aotani, E, et al. Difference of carboplatin clearance estimated by the Cockroft‐Gault, Jelliffe, Modified‐Jelliffe, Wright or Chatelut formula. Gynecol Oncol 2005, 99:327–333.
Mick, R, Ratain, MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991, 83:1560–1564.
Beal, SL, Sheiner, LB. Estimating population kinetics. Crit Rev Biomed Eng 1992, 8:195–222.
Bauer, RJ, Guzy, S, Ng, C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007, 9:E60–E83.
Mandema, JW, Verotta, D, Sheiner, LB. Building population pharmacokinetic‐pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992, 20:511–528.
Gallo, JM, Laub, PB, Rowinsky, EK, Grochow, LB, Baker, SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000, 18:2459–2467.
Rowland, M, Peck, C, Tucker, G. Physiologically‐based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011, 51:45–73.
Ballesta, A, Zhou, Q, Zhang, X, Lv, H, Gallo, JM. Multiscale design of cell‐type‐specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol 2014, 3:e112.
Willmann, S, Lippert, J, Schmitt, W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005, 1:159–168.
Zhang, XY, Birtwistle, MR, Gallo, JM. A general network pharmacodynamic model‐based design pipeline for customized cancer therapy applied to the VEGFR pathway. CPT Pharmacometrics Syst Pharmacol 2014, 3:e92.
Iyengar, R, Zhao, S, Chung, SW, Mager, DE, Gallo, JM. Merging systems biology with pharmacodynamics. Sci Transl Med 2012, 4:126ps127.
Keizer, RJ, Schellens, JH, Beijnen, JH, Huitema, AD. Pharmacodynamic biomarkers in model‐based drug development in oncology. Curr Clin Pharmacol 2011, 6:30–40.
Linnekamp, JF, Wang, X, Medema, JP, Vermeulen, L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res 2015, 75:245–249.
Intlekofer, AM, Younes, A. Precision therapy for lymphoma—current state and future directions. Nat Rev Clin Oncol 2014, 11:585–596.
Du, W, Elemento, O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene 2014 (Epub ahead of print; September 15, 2014).
Lee, MJ, Ye, AS, Gardino, AK, Heijink, AM, Sorger, PK, MacBeath, G, Yaffe, MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780–794.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061–1068.
Schwanhausser, B, Busse, D, Li, N, Dittmar, G, Schuchhardt, J, Wolf, J, Chen, W, Selbach, M. Global quantification of mammalian gene expression control. Nature 2011, 473:337–342.
Pascal, LE, True, LD, Campbell, DS, Deutsch, EW, Risk, M, Coleman, IM, Eichner, LJ, Nelson, PS, Liu, AY. Correlation of mRNA and protein levels: cell type‐specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008, 9:246.
Lu, P, Vogel, C, Wang, R, Yao, X, Marcotte, EM. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 2007, 25:117–124.
Ingolia, NT, Ghaemmaghami, S, Newman, JR, Weissman, JS. Genome‐wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 2009, 324:218–223.
Larsson, O, Tian, B, Sonenberg, N. Toward a genome‐wide landscape of translational control. Cold Spring Harb Perspect Biol 2013, 5:a012302.
Gutenkunst, RN, Waterfall, JJ, Casey, FP, Brown, KS, Myers, CR, Sethna, JP. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput Biol 2007, 3:1871–1878.